Youcheng Zhang

Youcheng Zhang


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in Pain Medicine
Verified
Journal Article
Closed access
PDF file
MWMan Cai Wang
Man Cai Wang
LZLing Yi Zhang
Ling Yi Zhang
YZYu Long Zhang
Yu Long Zhang
YZYa Wu Zhang
Ya Wu Zhang
XXXiao Dong Xu
Xiao Dong Xu
YZYoucheng Zhang
Youcheng Zhang

1 December 2014 in Medicine
Verified
Journal Article
Open access
MWMan Cai Wang
Man Cai Wang
LZLing Yi Zhang
Ling Yi Zhang
WHWei Han
Wei Han
YSYuan Shao
Yuan Shao
MCMo Chen
Mo Chen
YZYoucheng Zhang
Youcheng Zhang
Vedolizumab is an anti-inflammatory monoclonal antibody that exclusively targets the α4β7 integrin. We aimed to systematically review the efficacy and safety of vedolizumab for patients with inflammatory bowel diseases (IBDs). PubMed, EMBASE, and the Cochrane Library were searched up to May 2014. Randomized controlled trials examining the efficacy or safety of vedolizumab in patients with IBDs were eligible for inclusion. Data were extracted independently by 2 investigators and pooled using Review Manager 5.0 software (The Cochrane Collaboration, Copenhagen). Results were expressed as the relative risk (RR) with 95% confidence intervals (CIs). Six randomized controlled trials involving 2815 patients were eligible for inclusion. Vedolizumab was more effective than placebo for patients with ulcerative colitis and Crohn disease (CD) in clinical response (RR=1.82, 95% CI, [1.43, 2.31]; RR=1.46, 95% CI [1.18,1.81]) and clinical remission (RR=2.23, 95% CI [1.35, 3.68]; RR=1.71, 95% CI [1.25, 2.34]) during induction therapy. A superior effect was found during maintenance therapy in durable clinical/CD Activity Index-100 response (RR=2.22, 95% CI [1.62, 3.05]; RR=1.48, 95% CI [1.13, 1.94]) and clinical remission (RR=2.55, 95% CI [1.38, 4.70]; RR=1.15, 95% CI [0.75, 1.77]). However, vedolizumab may be associated with serious adverse events (RR=1.25, 95% CI [1.03, 1.52]) and nasopharyngitis (RR=1.56, 95% CI [1.08, 2.25]) for patients with CD. Vedolizumab was more effective than placebo as induction and maintenance therapy for IBDs, with an acceptable short-term safety profile, and achieving cure, although it may be associated with serious adverse events and nasopharyngitis for patients with CD.

1 January 2017 in Gastroenterology Research and Practice
Verified
Journal Article
Open access
PDF file
PLPeng Cheng Liu
Peng Cheng Liu
YYYu Ke Yan
Yu Ke Yan
YMYu Jing Ma
Yu Jing Ma
XWXiang Wen Wang
Xiang Wen Wang
JGJie Geng
Jie Geng
YZYoucheng Zhang
Youcheng Zhang
Background.We performed this meta-analysis to investigate the efficacy of probiotics on prevention of infection-related complications following colorectal resection.Method.PubMed, EMBASE, Cochrane Library, and the Web of Science were searched up to January 2016. According to the results, only randomized controlled trials that compared the efficacy of probiotics on patients with colorectal resection were included for meta-analysis.Results.Nine studies including a total of 1146 patients met the criteria (556 received multistrain probiotic bacteria, 590 with non-multistrain probiotic bacteria). The combination of multistrain probiotics was beneficial in the reduction of total infections (OR = 0.30, 95%CI: 0.15–0.61,p=0.0009), including surgical site infections (SSI) (OR = 0.48, 95%CI: 0.25–0.89,p=0.02) and nonsurgical site infections (NSSI) (OR = 0.36, 95%CI: 0.23–0.56,p<0.00001). However, there was no significant reduction in total infections (OR = 0.74, 95%CI: 0.50–1.09,p=0.13) or SSI (OR = 0.77, 95%CI: 0.52–1.12,p=0.17) with the application of non-multistrains of probiotics.Conclusion.Combinations of multistrain probiotic bacteria showed promise in preventing the incidence of infections following colorectal surgery. However, the efficacy of one or two strains of probiotics remains undetermined.

11 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
HDHongyang Deng
Hongyang Deng
JZJiaxing Zhang
Jiaxing Zhang
FWFahong Wu
Fahong Wu
FWFengxian Wei
Fengxian Wei
WHWei Han
Wei Han
YZYoucheng Zhang
Youcheng Zhang
The lymphatic system is a channel for fluid transport and cell migration, but it has always been controversial in promoting and suppressing cancer. VEGFC/VEGFR3 signaling has long been recognized as a major molecular driver of lymphangiogenesis. However, many studies have shown that the neural network of lymphatic signaling is complex. Lymphatic vessels have been found to play an essential role in the immune regulation of tumor metastasis and cardiac repair. This review describes the effects of lipid metabolism, extracellular vesicles, and flow shear forces on lymphangiogenesis. Moreover, the pro-tumor immune tolerance function of lymphatic vessels is discussed, and the tasks of meningeal lymphatic vessels and cardiac lymphatic vessels in diseases are further discussed. Finally, the value of conversion therapy targeting the lymphatic system is introduced from the perspective of immunotherapy and pro-lymphatic biomaterials for lymphangiogenesis.

18 May 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
MWMancai Wang
Mancai Wang
XXXiaofeng Xie
Xiaofeng Xie
SZSongbo Zhao
Songbo Zhao
XMXiaojuan Ma
Xiaojuan Ma
ZWZheyuan Wang
Zheyuan Wang
YZYoucheng Zhang
Youcheng Zhang
Objective: Whether fecal microbiota transplantation (FMT) in patients with irritable bowel syndrome (IBS) is effective in improving outcomes remains controversial. We assessed the safety and efficacy of FMT for patients with IBS.Methods: In this systematic review and meta-analysis, we searched PubMed, Embase, Web of Science, the Cochrane Library, the clinicaltrials.gov and International Clinical Trials Registry Platform (ICTRP) up to February 25, 2022, updated to March 28, 2023. Randomized controlled trials (RCTs) compared the stool and capsule FMT with placebo in patients with IBS were included. Two authors independently assessed study eligibility, extracted the data, and assessed risk of bias. We did meta-analysis with RevMan, and the Stata software was used for sensitivity analysis and meta-regression. The GRADE system was used to assess the quality of evidences. Mean difference (MD) or standardized Mean difference (SMD) with 95% CI for continuous data, and risk ratios (RR) with 95% CI for dichotomous data were used with random-effects models. The primary outcomes included the clinical response rate and IBS-SSS score. This study is registered with PROSPERO: CRD42022328377.Results: Nineteen reports from nine RCTs were included finally. Compared with the placebo, a single stool FMT could significantly decrease the IBS-SSS score at 1 month (MD=-65.75, 95%CI [-129.37, -2.13]), 3 months (MD=-102.11, 95% CI [-141.98, -62.24]), 6 months (MD=-84.38, 95%CI [-158.79, -9.97]), 24 months (MD=-110.41, 95%CI [-145.37, -75.46]), and 36 months (MD=-104.71, 95%CI [-137.78, -71.64]). It also could improve the clinical response rate at 3 months (RR=1.91, 95% [1.12, 3.25]), 24 months (RR=2.97, 95% [1.94, 4.54]), and 36 months (RR=2.48, 95% [1.65, 3.72]), and increase the IBS-QoL score at 3 months, 24 months, and 36 months. FMT did not increase the serious adverse event. The risk of bias was low, and the quality of evidence based on GRADE system was moderate in the stool FMT group. However, we did not find positive effect of capsule FMT on patients with IBS based on the current available data.Conclusion: A single stool FMT is effective and safe for patients with IBS. However, some factors may affect the effectiveness of FMT, and the relationship between the gut microbiome and the effect of FMT for IBS is still unclear.Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42022328377.